ONCOGENEX PHARMACEUTICALS, INC. 4
4 · ONCOGENEX PHARMACEUTICALS, INC. · Filed Jun 14, 2017
Insider Transaction Report
Form 4
Cormack Scott Daniel
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2017-06-12+5,000→ 89,055 total(indirect: By Spouse) - Exercise/Conversion
Restricted Stock Unit (RSU)
2017-06-12−5,000→ 5,000 total(indirect: By Spouse)Exp: 2018-06-12→ Common Stock (5,000 underlying) - Tax Payment
Common Stock
2017-06-12$0.36/sh−4,472$1,610→ 144,953 total - Exercise/Conversion
Common Stock
2017-06-12+9,375→ 149,425 total - Exercise/Conversion
Restricted Stock Unit (RSU)
2017-06-12−9,375→ 9,375 totalExp: 2018-06-12→ Common Stock (9,375 underlying)
Footnotes (4)
- [F1]Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
- [F2]Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of RSUs and does not represent a sale by the reporting person.
- [F3]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
- [F4]Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually each anniversary of June 12, 2014, subject to the reporting person's provision of service to the issuer on each vesting date.